Ceregene, Inc.
http://www.ceregene.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ceregene, Inc.
Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation
Ekso Bionics’ exoskeleton received a final payment determination from the Centers for Medicare and Medicaid Services, paving the way to faster rehabilitation for more patients.
Novartis Expands In Protein Degradation, Complements Radioligand Platform With Arvinas Deal
Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.
Merck KGaA Is Latest Partner For C4 Therapeutics’ Protein Degradation
New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice